Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Genelux logo — company profile

Genelux

Founded 2001 United States Westlake Village, United States 34 employees Post-IPO Equity Total: $98.98M Biopharma, Biotechnology +1

General Information

Company Name Genelux
Founded Year 2001
Location United States Westlake Village, United States
Founders / Decision Makers
Team member
Employees 34
Industries Biopharma, Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Genelux. To contact Genelux, visit genelux.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Genelux compare?

A PDF of Genelux and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Genelux soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Genelux

Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology firm founded in 2001 and based in the United States. The company operates at the forefront of the Biopharma, Biotechnology, and Health Care industries, focusing on oncolytic immunotherapy to improve patient outcomes in cases of challenging solid tumors.

Their proprietary ChoiceTM Discovery Platform underpins the development of a robust pipeline of therapies, with Olvi-Vec being their leading candidate currently undergoing a Phase 3 clinical trial for Platinum-Resistant/Refractory Ovarian Cancer (PRROC). Beyond PRROC, Olvi-Vec is also in development for Non-Small Cell Lung Cancer (NSCLC), recurrent Small Cell Lung Cancer (SCLC), and recurrent Ovarian Cancer.

Recently, Genelux secured a $27.50M Post-IPO Equity investment on 24 May 2024, further bolstering their pursuit of next-generation cancer therapies and reinforcing their commitment to innovative healthcare solutions.

Business keywords: oncolytic immunotherapy, solid tumors, cancer treatment, clinical-stage biotech, viral therapy, immunotherapies, clinical trials, cancer research, cancer therapy, personalized medicine

Services & Products

Development of oncolytic immunotherapy
Clinical trial management
Expanded access programs

Target Customers

Cancer patients Healthcare professionals Clinical researchers

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $27.50M -
24 May 2024
Post IPO Equity $18.00M -
12 Jun 2023
Post IPO Equity $33.00M -
15 May 2023
Convertible Note $20.00M 1
Woodward Diversified Capital
Woodward Diversified Capital
25 Sep 2020
Venture Round $481.27K -
06 Jun 2012

Genelux Alternatives & Competitors

View All Alternatives
Genelux vs
Prescient Therapeutics
Prescient Therapeutics Australia

A clinical stage oncology company developing personalised medicine approaches to cancer; cellular &...

Post-IPO Equity
14 employees
Biopharma, Biotechnology
Genelux vs
Seneca Therapeutics, Inc.
Seneca Therapeutics, Inc. United States

Seneca Therapeutics is developing a novel cancer therapy (oncolytic immunotherapeutic) for patients...

Series B
10 employees
Biopharma, Biotechnology
Genelux vs
OncXerna Therapeutics
OncXerna Therapeutics United States

Advancing a new paradigm of precision oncology with a RNA-based approach to match patients to novel,...

Venture round
8 employees
Biopharma, Biotechnology
Compare Genelux vs OncXerna Therapeutics
View all alternatives

FAQ About Genelux

Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to-treat solid tumors. Our ChoiceTM Discovery Platform is the foundation of our oncolytic immunotherapy development, having produced over 500 different v...
Genelux was founded in 2001.
Genelux is headquartered in Westlake Village, United States.
Genelux operates in Biopharma, Biotechnology and Health Care. Its work centres on oncolytic immunotherapy, solid tumors, cancer treatment and clinical-stage biotech. Its customers include Cancer patients, Healthcare professionals and Clinical researchers.
Genelux has approximately 34 employees.
Genelux has completed 5 funding rounds, raising a total of $98.98M. The latest funding stage is Post-IPO Equity.
Genelux offers: Development of oncolytic immunotherapy, Clinical trial management, Expanded access programs.
Top alternatives and competitors to Genelux include Prescient Therapeutics, Seneca Therapeutics, Inc., OncXerna Therapeutics , Genprex, Inc., ImmuneBridge. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Genelux and Prescient Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Genelux, https://bouncewatch.com/company/genelux, updated 2 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes